Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi : India Plans to Sell Pharmaceutical Manufacturing Site in India to Zentiva

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/11/2019 | 02:32am EDT

By P.R.Venkat

Sanofi India said it is planning to sell a pharmaceutical manufacturing facility in the western Indian state of Gujarat to Zentiva.

Sanofi India, a unit of France-based Sanofi, is selling the Ankleshwar site for 2.62 billion Indian rupees ($36.4 million), the company said in a statement on Wednesday.

The Ankleshwar site has a chemistry and biotechnology development centre, and manufactures both intermediates and pharmaceutical formulations. Sanofi's Ankleshwar site manufactures more than six billion tablets annually that include painkiller brands like Combiflam.

Write to venkat.pr@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
SANOFI -0.30% 79.53 Real-time Quote.5.12%
SANOFI INDIA LTD 0.07% 5927.65 End-of-day quote.-6.64%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
09/13HAGENS BERMAN : National Class-Action Lawsuit Accuses Sanofi of Concealing Zanta..
BU
09/13SANOFI : FDA Finds Probable Carcinogen in Some Versions of Zantac --Update
DJ
09/13SANOFI : FDA Finds Probable Carcinogen in Some Versions of Zantac --Update
DJ
09/13SANOFI : FDA Finds Probable Carcinogen in Some Versions of Zantac
DJ
09/13DISCOVER FINANCIAL SERVICES : Names Greene as Financial Chief
DJ
09/11SANOFI : India Plans to Sell Pharmaceutical Manufacturing Site in India to Zenti..
DJ
09/10LEXICON PHARMACEUTICALS : Sanofi to pay Lexicon $260 million for terminated part..
RE
09/10LEXICON PHARMACEUTICALS : Says It Terminated Sanofi Alliance
DJ
08/30Novartis takes aim at Roche's star MS drug
RE
08/29United States Over The Counter Drugs Market Analysis Potential Growth, Demand..
AQ
More news
Financials (EUR)
Sales 2019 36 254 M
EBIT 2019 9 474 M
Net income 2019 4 196 M
Debt 2019 14 641 M
Yield 2019 3,96%
P/E ratio 2019 25,5x
P/E ratio 2020 16,8x
EV / Sales2019 3,15x
EV / Sales2020 2,97x
Capitalization 99 582 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Average target price 88,57  €
Last Close Price 79,53  €
Spread / Highest target 25,7%
Spread / Average Target 11,4%
Spread / Lowest Target -0,67%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI5.12%110 279
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
MERCK AND COMPANY8.11%211 513
PFIZER-15.44%204 151
NOVARTIS18.45%200 777